Table 3 Chromatin-modifying agents under investigation for MPN therapy
From: Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies
Agent | Brand Name | Pharmaceutical company | Mechanism of action | Phase of study in MPN |
|---|---|---|---|---|
Histone deacetylase inhibitors | ||||
LBH589 | Panobinostat | Novartis | Class I/II HDAC inhibition | I/II |
HSP 90 inhibition | ||||
ITF2357 | Givinostat | Italfarmaco | Class I/II HDAC inhibition | II |
HSP90 inhibition | ||||
Suberoylanilide hydroxamic acid | Vorinostat | Merck | Class I/II HDAC inhibition | None |
HSP90 inhibition | ||||
DNA methyltransferase inhibitors | ||||
Azacitidine | Vidaza | Celgene | DNA methyltransferase I inhibition | Phase II |
Decitabine | Dacogen | Eisai | DNA methyltransferase I inhibition | Phase II |